How can countries cope with more than one major respiratory virus spreading, while non- pharmaceutical interventions are being loosened week by week?

What about:

  • The possible co-circulation of influenza viruses, SARS-CoV-2, and RSV?
  • Who belongs to high risk groups?
  • Who to vaccinate and against what?
  • Guidelines and regulations for co-vaccination?
  • Forecasts on vaccine development?
  • The use of anti-virals and antibodies during different stages of the respective infections?

Each of these challenges have been addressed in our 2021 ESWI Webinar Series.

The conclusions and recommendations can be downloaded here!

Check out the FULL VERSIONS of the webinars and the take home messages

 
programme

 

5 Completed webinars:

Webinar:
Monday 20 September 2021 | 16:00 - 17:30 (CEST)
completed
Lecture 1
Introductory talk on Vaccination in a COVID-19 era
Sylvie van Der Werf , Institut Pasteur , France Bio
Lecture 2
Risk Groups: impact of viral infection during pregnancy on immunity of offspring
Gülsah Gabriel , Heinrich Pette Institute , Germany Bio
Lecture 3
Vaccine innovation: Developing an Ad26-based Covid vaccine
Jenny Hendriks , Janssen Vaccines & Prevention , The Netherlands Bio
Lecture 4
Equitable Vaccine Distribution
Lwazi Manzi , Head of Secretariat of the African Union Commission on COVID-19 , South Africa Bio
Lecture 5
Closing remarks and take home message
Ab Osterhaus , ESWI Chair, TiHO , Germany Bio

Take home message

Webinar:
Monday 27 September 2021 | 16:00 - 17:30 (CEST)
completed
Lecture 1
Introductory talk on Childhood Influenza Vaccination and treatment in a COVID-19 era
George Kassianos , National Immunisation Lead Royal College of General Practitioners , United Kingdom Bio
Lecture 2
The UK’s experience in Vaccinating Healthy Children - are there any benefits?
George Kassianos , National Immunisation Lead Royal College of General Practitioners , United Kingdom Bio
Lecture 3
Vaccinating children against COVID-19
Florian Krammer , Icahn School of Medicine at Mount Sinai , United States of America Bio
Lecture 4
ImmuHubs: Improving access to vaccination in disadvantaged and difficult to reach populations
Barbara Rath , Vienna Vaccine Safety Initiative , Germany Bio
Lecture 5
Closing remarks and take home message
Ab Osterhaus , ESWI Chair, TiHO , Germany Bio

Take home message

Webinar:
Monday 4 October 2021 | 16:00 - 17:30 (CEST)
completed
Lecture 1
Sprint through most recent COVID-19 literature on treatment options
Marco Goeijenbier , Erasmus MC , The Netherlands Bio
Lecture 2
Cost-effectiveness of dexamethasone, tocilizumab and remdesivir in ICU patients with COVID
Brooke Nichols , Boston University , The Netherlands Bio
Lecture 3
Anti-viral treatment of COVID-19
Mike Ison , Northwestern University , United States of America Bio
Lecture 4
Immune modulatory treatment in severe COVID-19
Rik Endeman , Erasmus MC , The Netherlands Bio
Lecture 5
Closing remarks and take home message
Ab Osterhaus , ESWI Chair, TiHO , Germany Bio

Take home message

Webinar:
Monday 11 October 2021 | 16:00 - 17:30 (CEST)
completed
Lecture 1
Introductory talk on RSV in a COVID-19 era
Peter Openshaw , Imperial College London , United Kingdom
Peter Openshaw
Lecture 2
Burden of RSV disease in infants: The need for All Infant Protection
Michelle Roberts , Sanofi Pasteur , United States of America Bio
Lecture 3
The burden of RSV disease in older adults
Dexter Wiseman , National Health Service , United Kingdom Bio
Lecture 4
How do we prepare for the future?
Ab Osterhaus , ESWI Chair, TiHO , Germany Bio
Lecture 5
Closing remarks and take home message
Ab Osterhaus , ESWI Chair, TiHO , Germany Bio

Take home message

Webinar:
Wednesday 17 November 2021 | 16:00 - 17:30 (CET)
completed
Lecture 1
Introductory talk on Flu and COVID-19 Booster Vaccinations
Rebecca Cox , University of Bergen , Norway Bio
Lecture 2
Australia's approach to Influenza vaccination in a COVID season
Rodney Pearce , Australian Immunisation Coalition , Australia Bio
Lecture 3
Social Distancing, Lockdown and the Wide Use of Mask; A Magic Solution or a Double-Edged Sword for Respiratory Viruses Epidemiology?
Raul Ortiz de Lejarazu Leonardo , National Influenza Center , Spain Bio
Lecture 4
The safety and immunogenicity of concomitant administration of COVID-19 vaccines with seasonal influenza vaccines in adults
Rajeka Lazarus , Bristol Vaccine Centre , United Kingdom Bio
Lecture 5
Closing remarks and take home message
Rebecca Cox , University of Bergen , Norway Bio

Take home message

ESWI partner organisations